United States
Print page content Print
Increase text size Decrease text size
Text Size
Cytopoint logo
Cytopoint Professional Efficacy Skin Healing Hero Image

CYTOPOINT™ gives damaged skin a chance to heal
after 1 injection1

*Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1

Significantly different compared to placebo (P≤0.05).

Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

Reference: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis LLC.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2016 Zoetis Services LLC. All rights reserved. CYT-00090

STUDY DESIGN

A single 2.0 mg/kg dose of CYTOPOINT (n=50) or placebo (n=52) was administered subcutaneously on Day 0 in this randomized, double-blind, placebo-controlled study of dogs diagnosed with atopic dermatitis. The primary effectiveness endpoints were treatment success in pruritus as assessed by owners on a VAS (success defined as a ≥20 mm reduction in pruritus scores compared to Day 0) and by investigators with CADESl-03 (success defined as a ≥50% decrease in CADESl-03 score compared to Day 0).1